A named product, route, population and condition.
Spravato has specific adult depression indications and a supervised REMS program. Approval does not spread from one product or use to everything called psychedelic medicine.
Psychedelics · California · evidence Aug 28 · registry Aug 31
Psychedelic treatment in California.
The altered state is not the evidence.
Ten drugs and drug families are often placed under one bright word. Their approval status, evidence and medical oversight are not remotely the same.
Evidence and regulatory status checked August 28, 2026; registry status checked August 31, 2026. Licensed-prescriber and legal review are pending; no review badge is claimed.
Four terms that should not blur
Approved use, off-label use, an unapproved product and research are different doors.
An approved drug used for a use FDA did not approve.
Ketamine injection is approved as an anesthetic. Psychiatric use of the approved injection is off-label; FDA has not approved that use for depression, PTSD or anxiety.¹⁰ ¹²
Compounding does not inherit an ingredient’s approval.
A compounded ketamine product is not FDA-approved and has no FDA-approved indication or route. Ask which product, formulation, route and pharmacy are involved.¹³
A protocol asks a question; it does not sell a settled answer.
Psilocybin, MDMA, LSD, DMT, methylone, ibogaine and the sponsor-coded compounds on this desk remain investigational. An IND, Phase 3 record or development designation is not approval.¹
The short answer
No statewide licensed psilocybin or MDMA therapy system appeared in this dated official-source review.
Psilocybin and MDMA remain investigational and federally controlled. So do the LSD, DMT, ibogaine, methylone, ayahuasca and mescaline routes named below. FDA-approved ketamine injection may be prescribed off-label for psychiatric care; compounded ketamine products are not FDA-approved. Esketamine has specific FDA-approved depression uses and a required supervised safety program. “Decriminalized,” “breakthrough,” and “allowed to enter a trial” do not mean “approved treatment.”¹ ² ³ ¹⁰ ¹² ¹³
Ten names · ten different answers
Name the drug before you judge the offer.
01InvestigationalPsilocybin
A trial is not a clinic.
Psilocybin is not FDA-approved. A registered study is the research route. A paid “facilitation” service is not FDA-approved treatment, and this dated official-source review identified no statewide California psilocybin service-center system.
→02InvestigationalMDMAPromising PTSD results did not create an approved treatment.
MDMA remains federally controlled and is not FDA-approved for PTSD. Established PTSD care and registered trials remain the treatment routes.
→03Approved injection · psychiatric use off-labelKetamineApproved anesthetic; psychiatric use off-label.
FDA-approved ketamine injection is an anesthetic. Psychiatric use of the approved injection is off-label; compounded ketamine products are not FDA-approved. The exact product, route, prescriber, monitoring, emergency plan and full course price are part of the decision.
→04FDA-approved usesEsketamineA specific drug, label and supervised program.
Spravato has FDA-approved adult depression indications. It is administered in a certified setting with at least two hours of monitoring—not dispensed for use at home.
→05InvestigationalLSD / lysergideA phase 3 study is still a study.
California research includes investigational lysergide for depression and anxiety. A recruiting registry record does not create approved LSD-assisted therapy.
→06InvestigationalDMT / 5-MeO-DMTMechanism research is not clinical care.
A California DMT study is designed for healthy participants. No FDA-approved DMT or 5-MeO-DMT mental-health treatment exists.
→07InvestigationalIbogaine / noribogaineObservation is not access.
A recruiting California ibogaine record observes people with MRI and EEG; it does not provide ibogaine treatment. An allowed IND is not approval.
→08InvestigationalMethyloneAn entactogen under study—not MDMA by another name.
A California phase 3 PTSD study is recruiting. Methylone remains investigational and the study decides eligibility.
→09No statewide CA system identifiedAyahuascaA ceremony is not a registered treatment pathway.
There is no FDA-approved mental-health use. This dated official-source review identified no statewide California licensed-treatment system or recruiting California treatment study.
→010No statewide CA system identifiedMescalineA traditional history is not regulatory approval.
There is no FDA-approved mental-health use. This dated official-source review identified no statewide California licensed-treatment system or recruiting California treatment study.
→Psilocybin evidence
A real signal. A research-stage answer.
Randomized phase 2 studies reported reductions in depression scores after supervised psilocybin with psychological support. The trials were small compared with ordinary drug-approval programs, selected participants carefully, and do not establish a safe consumer service for everyone. One treatment-resistant-depression study did not show a sustained response through 12 weeks on its key sustained measure.⁴ ⁵
FDA’s July 2026 final guidance exists because psychedelic trials have unusual problems: masking is difficult, psychological support may affect the result, effects can last for hours, and safety monitoring matters. Guidance for research is not approval of a drug.¹
Compare the evidence by exact substance and condition →California is not a single permission slip
“Decriminalized” does not mean licensed treatment.
California’s statewide decriminalization bill, SB 58, was vetoed in 2023. A local decision to make enforcement a lower priority does not create FDA approval, a statewide service-center system, or a California health-care licence.⁷ ¹¹
A licensed therapist may help you discuss risks or make sense of a difficult experience without supplying or administering a controlled drug. Ask where psychotherapy ends, who prescribes or supplies the substance, which licence governs each person, and who is medically responsible during the drug session. “Psychedelic facilitator” alone answers none of those questions.
Test the words in an offer →MDMA and PTSD
A positive trial and an approved treatment are different events.
Phase 3 trials reported improvement in PTSD symptoms with MDMA-assisted therapy. MDMA nevertheless remains unapproved and federally controlled. FDA convened an advisory committee on the application in 2024; an advisory meeting and a development program do not themselves authorize clinical use.³ ⁶
If you need PTSD care now, compare established trauma treatments. If you want research participation, verify the study in the federal registry and read its eligibility, location, sponsor and recruitment status yourself.
Beyond the familiar four
Research activity does not flatten the differences.
LSD / lysergide: California phase 3 depression research includes recruiting and not-yet-recruiting sites. Other anxiety and depression studies remain active but are not recruiting. The drug is investigational.
DMT and 5-MeO-DMT: a La Jolla DMT record is not yet recruiting healthy participants for a neural-effects study. The active California 5-MeO-DMT record is observational, combines several interventions, and is not recruiting.
Ibogaine and noribogaine: FDA allowed an early-phase noribogaine IND to proceed in 2026; the agency explicitly says that permission to study is not approval or a finding of safety or effectiveness. The recruiting UC Irvine ibogaine record is observational and does not supply the drug.⁸
Methylone: this entactogen is not MDMA. A phase 3 PTSD study lists recruiting California sites, but methylone remains investigational.
Ayahuasca and mescaline: no recruiting California treatment study appeared in the August 28 registry snapshot. Neither has an FDA-approved mental-health use, and this dated official-source review identified no statewide California licensed-treatment system for either one.
Open the California clinical-trial desk →Before you pay
Make the offer survive six ordinary questions.
- What exact drug, dose and route are you offering?“Psychedelic medicine” is not a medication name.
- Which lane is this: an FDA-approved use, off-label use of an approved drug, a compounded product that is not FDA-approved, registered research, or another service?These are different approval, evidence and accountability lanes.
- Who prescribes or administers it, and what California licence do they hold?Verify the licence independently; a training certificate is not a state health-care licence.
- Who screens for psychosis, mania, heart risk, medicines and substance use?A ceremonial intake is not a medical risk assessment.
- What can the setting manage if blood pressure rises, breathing changes or I become confused?Ask what happens onsite, not merely which emergency room is nearby.
- What is the complete price through follow-up?Include screening, drug sessions, monitoring, preparation, integration and maintenance.
The registered research route
A study record should answer more questions than an advertisement.
Use ClinicalTrials.gov. Confirm the official study contact on the registry, then ask about eligibility, randomization, placebo or comparator, travel, costs, compensation, follow-up and who pays for an injury. Never pay a third party merely to put you on a “trial waitlist.”
No clinic rankings. No miracle arithmetic. No legality by implication.
We do not rank providers, repeat testimonials, or call a local enforcement policy a treatment licence. Future directory results will use your filters and verified facts. Payment will never purchase a higher position.
Is psychedelic therapy legal in California?
This dated official-source review identified no statewide licensed psilocybin or MDMA therapy system in California. FDA-approved ketamine injection may be prescribed off-label for psychiatric care; compounded ketamine products are not FDA-approved. Spravato has specific FDA-approved adult depression uses and a supervised REMS program. A city’s enforcement policy does not turn psilocybin into approved medicine or a licensed treatment service. This is a general regulatory distinction, not a legal judgment about a particular business.¹⁰ ¹² ¹³
The documents behind the distinctions.
- U.S. Food and Drug Administration, Psychedelic Drugs: Considerations for Clinical Investigations, final guidance issued July 2026.
- Drug Enforcement Administration, Psilocybin Drug Fact Sheet, federal Schedule I status.
- U.S. Food and Drug Administration, selected FDA activities, including the June 2024 MDMA advisory-committee meeting; FDA, Spravato prescribing information.
- Raison et al., single-dose psilocybin for major depressive disorder, randomized phase 2 trial, JAMA, 2023.
- Goodwin et al., single-dose psilocybin for treatment-resistant depression, phase 2 trial, New England Journal of Medicine, 2022.
- Mitchell et al., MDMA-assisted therapy for moderate to severe PTSD, phase 3 trial, Nature Medicine, 2023.
- Governor of California, SB 58 veto message, October 7, 2023. The proposed statewide decriminalization measure did not become law.
- ClinicalTrials.gov, California study records and recruitment-status definitions: 40 recruiting, not-yet-recruiting or invitation-only records, 17 active records closed to new participants, 3 status-unknown records, and 1 suspended record, queried and human-checked August 31, 2026.
- U.S. Food and Drug Administration, April 24, 2026 research actions: an early-phase noribogaine IND may proceed; FDA states this does not mean approval or a finding that the drug is safe or effective.
- U.S. Food and Drug Administration, Understanding Unapproved Use of Approved Drugs “Off Label”: an approved drug may be prescribed for an unapproved use based on a clinician’s medical judgment; FDA has not approved that use.
- California Legislature, Health and Safety Code §11054, current Schedule I text. This source does not itself decide the facts of any individual business or claimed exemption.
- U.S. Food and Drug Administration, Ketalar prescribing information, revised October 2025: ketamine hydrochloride injection for intravenous or intramuscular use is indicated as a general anesthetic.
- U.S. Food and Drug Administration, Compounding and the FDA: Questions and Answers and compounding risk alerts: compounded drugs are not FDA-approved, and FDA has warned about compounded ketamine products for psychiatric disorders.
Educational information, not individual medical or legal advice. Evidence and law checked August 28, 2026; registry status checked August 31, 2026. Licensed-prescriber and legal review are pending.